Clinical characteristics and survival of glioblastoma complicated with non-central nervous system tumors

Chinese Neurosurgical Journal

Research

Mingchen Yu¹  You Zhai¹  Jiazheng Zhang²  Changqing Pan²  Zhiliang Wang²  Chen Wang²  Cheng Cheng²  Di Wang²  Wei Zhang³  Guanzhang Li⁴ 

[1] Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Center of Brain Tumor, Beijing Institute for Brain Disorders, Beijing, China;China National Clinical Research Center for Neurological Diseases, Beijing, China;Chinese Glioma Genome Atlas (CGGA), Beijing, China;Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Beijing Neurosurgical Institute, Capital Medical University, No. 119 South Fourth Ring Western Road, Fengtai District, Beijing, China;Chinese Glioma Genome Atlas (CGGA), Beijing, China;

关键词: Glioblastoma;    Multiple primary tumors;    Clinical and pathological characteristics;    Prognosis;   

DOI  :  10.1186/s41016-022-00312-1

 received in 2022-10-28, accepted in 2022-12-07,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundDiagnosis and treatment of patients with glioblastoma (GBM) who are also diagnosed with primary non-central nervous system (CNS) tumors remain a challenge, yet little is known about the clinical characteristics and prognosis of these patients. The data presented here compared the clinical and pathological features between glioblastoma patients with or without primary non-CNS tumors, trying to further explore this complex situation.MethodsStatistical analysis was based on the clinical and pathological data of 45 patients who were diagnosed with isocitrate dehydrogenase (IDH) wild-type glioblastoma accompanied by non-CNS tumors between January 2019 and February 2022 in Beijing Tiantan Hospital. Univariate COX proportional hazard regression model was used to determine risk factors for overall survival.ResultsIt turned out to be no significant difference in the overall survival (OS) of the 45 patients with IDH-wild-type GBM plus non-CNS tumors, compared with the 112 patients who were only diagnosed with IDH-wild-type GBM. However, there was a significant difference in OS of GBM patients with benign tumors compared to those with malignant tumors.ConclusionsImplications for the non-central nervous system tumors on survival of glioblastomas were not found in this research. However, glioblastomas complicated with other malignant tumors still showed worse clinical outcomes.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

Fig. 3

Fig. 2

Fig. 1